Logo Logo
Hilfe
Hilfe
Switch Language to English

Perneczky, Robert ORCID logoORCID: https://orcid.org/0000-0003-1981-7435; Darby, David; Frisoni, Giovanni B.; Hyde, Robert; Iwatsubo, Takeshi ORCID logoORCID: https://orcid.org/0000-0003-1160-8129; Mummery, Catherine J.; Park, Kee Hyung ORCID logoORCID: https://orcid.org/0000-0001-6847-6679; Beek, Johan van ORCID logoORCID: https://orcid.org/0000-0002-5641-0004; Flier, Wiesje M. van der ORCID logoORCID: https://orcid.org/0000-0001-8766-6224 und Jessen, Frank (2025): Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus. In: Journal of Prevention of Alzheimer's Disease, Bd. 12, Nr. 4, 100096 [PDF, 806kB]

Abstract

Background: Many dementia and Alzheimer's disease (AD) registries operate at local or national levels without standardization or comprehensive real-world data (RWD) collection. This initiative sought to achieve consensus among experts on priority outcomes and measures for clinical practice in caring for patients with symptomatic AD, particularly in the mild cognitive impairment and mild to moderate dementia stages.

Objective: The primary aim was to define a minimum dataset (MDS) and extended dataset (EDS) to collect RWD in the new International Registry for AD and Other Dementias (InRAD) and other AD registries. The MDS and EDS focus on informing routine clinical practice, covering relevant comorbidities and safety, and are designed to be easily integrated into existing data capture systems.

Methods and results: An international steering committee (ISC) of AD clinician experts lead the initiative. The first drafts of the MDS and EDS were developed based on a previous global inter-societal Delphi consensus on outcome measures for AD. Based on the ISC discussions, a survey was devised and sent to a wider stakeholder group. The ISC discussed the survey results, resulting in a consensus MDS and EDS covering: patient profile and demographics; lifestyle and anthropometrics; co-morbidities and diagnostics; imaging; treatment; clinical characterization; safety; discontinuation; laboratory tests; patient and care partner outcomes; and interface functionality.

Conclusion: By learning from successful examples in other clinical areas, addressing current limitations, and proactively enhancing data quality and analytical rigor, the InRAD registry will be a foundation to contribute to improving patient care and outcomes in neurodegenerative diseases.

Dokument bearbeiten Dokument bearbeiten